Lista de obras -

"To patent or not to patent? the case of Novartis' cancer drug Glivec in India".

artículo científico publicado en 2014

A call for a moratorium on the .health generic top-level domain: preventing the commercialization and exclusive control of online health information

artículo científico publicado en 2014

Achieving a dream: meeting policy goals related to improving drug access

artículo científico publicado en 2010

An examination of pharmaceutical systems in severely disrupted countries

artículo científico publicado en 2012

Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort? ⬇️

artículo científico publicado el 1 de febrero de 2010

Canada's neglected tropical disease research network: who's in the core-who's on the periphery?

artículo científico publicado en 2013

Civil society participation in the health system: the case of Brazil's Health Councils

artículo científico publicado en 2016

Corporate social responsibility to improve access to medicines: the case of Brazil.

artículo científico publicado en 2017

Corruption in the health care sector: A barrier to access of orthopaedic care and medical devices in Uganda

artículo científico publicado en 2012

Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System

artículo científico publicado en 2015

Ensuring the future of health information online

artículo científico publicado en 2013

Finding flaws: the limitations of compulsory licensing for improving access to medicines--an international comparison.

artículo científico publicado en 2008

Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime

artículo científico publicado en 2010

Governance and pharmacovigilance in Brazil: a scoping review

artículo científico publicado en 2016

Health domains for sale: the need for global health Internet governance

artículo científico publicado en 2014

How to achieve international action on falsified and substandard medicines

artículo científico publicado en 2012

Matching safety to access: global actors and pharmacogovernance in Kenya- a case study

scientific article published on 23 March 2017

No More Broken Promises: Challenges and Opportunities for Key Populations in Demanding More Transparency, Accountability, and Participation in the Global Response Against the HIV and AIDS Epidemic

artículo científico publicado en 2017

Panel: Canada's law on global access to affordable medicines

artículo científico publicado en 2009

Participatory health councils and good governance: healthy democracy in Brazil?

artículo científico publicado en 2015

Policy versus practice: a community-based qualitative study of the realities of pharmacy services in Nunavut, Canada

artículo científico publicado en 2015

Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists

artículo científico publicado en 2012

Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance.

artículo científico publicado en 2017

The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines

article

The make or buy debate: Considering the limitations of domestic production in Tanzania ⬇️

artículo científico publicado el 29 de junio de 2012

The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access ⬇️

artículo científico publicado el 3 de abril de 2012

The role of supportive supervision on immunization program outcome - a randomized field trial from Georgia

artículo científico publicado en 2009

The success rate of new drug development in clinical trials: Crohn's disease.

artículo científico publicado en 2010

Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers

artículo científico publicado en 2009

Why the MDGs need good governance in pharmaceutical systems to promote global health

artículo científico publicado en 2014

Lista de obras de

"To patent or not to patent? the case of Novartis' cancer drug Glivec in India".

A call for a moratorium on the .health generic top-level domain: preventing the commercialization and exclusive control of online health information

Achieving a dream: meeting policy goals related to improving drug access

An examination of pharmaceutical systems in severely disrupted countries

Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort? ⬇️

Canada's neglected tropical disease research network: who's in the core-who's on the periphery?

Civil society participation in the health system: the case of Brazil's Health Councils

Corporate social responsibility to improve access to medicines: the case of Brazil.

Corruption in the health care sector: A barrier to access of orthopaedic care and medical devices in Uganda

Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System

Ensuring the future of health information online

Finding flaws: the limitations of compulsory licensing for improving access to medicines--an international comparison.

Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime

Governance and pharmacovigilance in Brazil: a scoping review

Health domains for sale: the need for global health Internet governance

How to achieve international action on falsified and substandard medicines

Matching safety to access: global actors and pharmacogovernance in Kenya- a case study

No More Broken Promises: Challenges and Opportunities for Key Populations in Demanding More Transparency, Accountability, and Participation in the Global Response Against the HIV and AIDS Epidemic

Panel: Canada's law on global access to affordable medicines

Participatory health councils and good governance: healthy democracy in Brazil?

Policy versus practice: a community-based qualitative study of the realities of pharmacy services in Nunavut, Canada

Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists

Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance.

The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines

The make or buy debate: Considering the limitations of domestic production in Tanzania ⬇️

The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access ⬇️

The role of supportive supervision on immunization program outcome - a randomized field trial from Georgia

The success rate of new drug development in clinical trials: Crohn's disease.

Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers

Why the MDGs need good governance in pharmaceutical systems to promote global health